Vimarsana
Biggest News Aggregation in the World

Page 31 - Biocon Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biocon Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biocon Ltd Today - Breaking & Trending Today

Indices: Stock market update: Nifty Pharma index falls 0.42% - Vimarsana News

Indices: Stock market update: Nifty Pharma index falls 0.42%

The Nifty Pharma index closed 0.42 per cent down at 15497.15.

Biocon's net profit doubles to Rs 172.7 crore in Q2 – India Education | Latest Education News | Global Educational News - Vimarsana News

Biocon's net profit doubles to Rs 172.7 crore in Q2 – India Education | Latest Education News | Global Educational News

Indian pharmaceutical giant Biocon on Friday reported a net profit of Rs 172.7 crore in the September quarter of financial year 2023-24, more than double its profit of Rs 81.8 crore in the same period of the previous year. According to the compa

Indices: Stock market update: Nifty Pharma index falls 0.18% in a weak market - Vimarsana News

Indices: Stock market update: Nifty Pharma index falls 0.18% in a weak market

The Nifty Pharma index was trading 0.18 per cent down at 15463.9.

Biocon's net profit doubles to Rs 172.7 crore in Q2 - Vimarsana News

Biocon's net profit doubles to Rs 172.7 crore in Q2

Indian pharmaceutical giant Biocon on Friday reported a net profit of Rs 172.7 crore in the September quarter of financial year 2023-24, more than double its profit of Rs 81.8 crore in the same period of the previous year.According to the ...

Biocon Q2: Biocon Q2 Results: Net profit zooms over two-fold to Rs 173 crore - Vimarsana News

Biocon Q2: Biocon Q2 Results: Net profit zooms over two-fold to Rs 173 crore

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. The gross R&D spends grew 10% YoY to Rs 278 crore in Q2FY24.